Evidence map›Paper›PMID 16861040›Full record

ReviewClinical immunology (Orlando, Fla.)2006

The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus.

Jim C Oates, Gary S Gilkeson

Open access · greenAbstract readReview
In one paragraph

Review in Clinical immunology (Orlando, Fla.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 76 citations in OpenAlex.

  1. Review
  2. Iron metabolism in rheumatic diseases.Journal of translational autoimmunity · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Understanding mechanisms of hypertension in systemic lupus erythematosus.Therapeutic advances in cardiovascular disease · 2016
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jim C OatesDepartment of Medicine, Division of Rheumatology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, PO Box 250637, Charleston, SC 29425, USA. oatesjc@musc.edu
Gary S Gilkeson
Medical University of South Carolina · US

Funding

ZINC AND COPPER METABOLISM IN COLLAGEN DISORDERSM01RR001070 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI REVES, JOSEPH G · 1985 to 2009
$16.3M
Role of nitric oxide and eicosanoids in lupus nepthritisK08AR002193 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI OATES, JAMES C · 2001 to 2005
$635k
NCRR NIH HHS M01 RR001070NIAMS NIH HHS K08 AR002193
6 · The paper itself

Abstract

Formation of reactive nitrogen and oxygen intermediates (RNI and ROI) is an essential part of the innate immune response. Markers of systemic RNI production are increased in the setting of systemic lupus erythematosus (SLE) activity. Several lines of evidence suggest mechanisms through which the activity of inducible nitric oxide synthase (iNOS) is pathogenic in SLE, including the ability of peroxynitrite (ONOO(-), a product of iNOS activity) to modify proteins, lipids, and DNA. These modifications can alter enzyme activity and may increase the immunogenicity of self antigens, leading to a break in immune tolerance. In humans, observational data suggest that overexpression of iNOS and increased production of ONOO(-) lead to glomerular and vascular pathology. Therapies designed to target iNOS activity or scavenge ROI and RNI are in development and may provide the means to reduce the pathogenic consequences of ROI and RNI in SLE.

Indexed as

AnimalsDisease Models, AnimalHumansLupus Erythematosus, SystemicNitric OxideNitric Oxide SynthaseReactive Nitrogen SpeciesReactive Oxygen SpeciesNitric OxideNitric Oxide SynthaseReactive Nitrogen SpeciesReactive Oxygen Species

Identifiers

PMID16861040
PMCPMC2765327
OpenAlexW2025203589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.